<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I - Jameson, E - 2019 | Cochrane Library</title> <meta content="Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I - Jameson, E - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009354.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I - Jameson, E - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009354.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009354.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I" name="citation_title"/> <meta content="Elisabeth Jameson" name="citation_author"/> <meta content="Central Manchester University Hospitals NHS Foundation Trust" name="citation_author_institution"/> <meta content="elisabeth@doctors.org.uk" name="citation_author_email"/> <meta content="Simon Jones" name="citation_author"/> <meta content="Central Manchester University Hospitals NHS Foundation Trust" name="citation_author_institution"/> <meta content="Tracey Remmington" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD009354.pub5" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/06/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009354.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009354.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009354.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Enzyme Replacement Therapy [methods]; *Iduronidase [therapeutic use]; *Mucopolysaccharidosis I [drug therapy]; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009354.pub5&amp;doi=10.1002/14651858.CD009354.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="uYcNEb5O";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009354\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009354\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009354\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009354\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009354.pub5",title:"Enzyme replacement therapy with laronidase (Aldurazyme\\u00AE) for treating mucopolysaccharidosis type I",firstPublishedDate:"Jun 18, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009354.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009354.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009354.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009354.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009354.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009354.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009354.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009354.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009354.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009354.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3144 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009354.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/full#CD009354-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/full#CD009354-sec-0077"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/full#CD009354-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/full#CD009354-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/full#CD009354-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/full#CD009354-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/full#CD009354-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/full#CD009354-sec-0071"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/appendices#CD009354-sec-0082"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/table_n/CD009354StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/table_n/CD009354StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/information#CD009354-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Elisabeth Jameson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/information#CD009354-cr-0005">Simon Jones</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009354.pub5/information#CD009354-cr-0006">Tracey Remmington</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/information/en#CD009354-sec-0089">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 June 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009354.pub5">https://doi.org/10.1002/14651858.CD009354.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009354-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009354-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009354-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009354-abs-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009354-abs-0005">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009354-abs-0001" lang="en"> <section id="CD009354-sec-0001"> <h3 class="title" id="CD009354-sec-0001">Background</h3> <p>Mucopolysaccharidosis type I can be classified as three clinical sub‐types; Hurler syndrome, Hurler‐Scheie syndrome and Scheie syndrome, with the scale of severity being such that Hurler syndrome is the most severe and Scheie syndrome the least severe. It is a rare, autosomal recessive disorder caused by a deficiency of alpha‐L‐iduronidase. Deficiency of this enzyme results in the accumulation of glycosaminoglycans within the tissues. The clinical manifestations are facial dysmorphism, hepatosplenomegaly, upper airway obstruction, skeletal deformity and cardiomyopathy. If Hurler syndrome is left untreated, death ensues by adolescence. There are more attenuated variants termed Hurler‐Scheie or Scheie syndrome, with those affected potentially not presenting until adulthood. Enzyme replacement therapy has been used for a number of years in the treatment of Hurler syndrome, although the current gold standard would be a haemopoietic stem cell transplant in those diagnosed by 2.5 years of age. This is an updated version of the original Cochrane Review published in 2013 and previously updated in 2015. </p> </section> <section id="CD009354-sec-0002"> <h3 class="title" id="CD009354-sec-0002">Objectives</h3> <p>To evaluate the effectiveness and safety of treating mucopolysaccharidosis type I with laronidase enzyme replacement therapy as compared to placebo. </p> </section> <section id="CD009354-sec-0003"> <h3 class="title" id="CD009354-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Inborn Errors of Metabolism Trials Register, MEDLINE via OVID and Embase. </p> <p>Date of most recent search: 30 January 2019.</p> </section> <section id="CD009354-sec-0004"> <h3 class="title" id="CD009354-sec-0004">Selection criteria</h3> <p>Randomised and quasi‐randomised controlled studies of laronidase enzyme replacement therapy compared to placebo. </p> </section> <section id="CD009354-sec-0005"> <h3 class="title" id="CD009354-sec-0005">Data collection and analysis</h3> <p>Two authors independently screened the identified studies. The authors then appraised and extracted data. The quality of the evidence was assessed using GRADE. </p> </section> <section id="CD009354-sec-0006"> <h3 class="title" id="CD009354-sec-0006">Main results</h3> <p>One study (45 participants) met the inclusion criteria. This double‐blind, placebo‐controlled, randomised, multinational study looked at laronidase at a dose of 0.58 mg/kg/week versus placebo in people with mucopolysaccharidosis type I. All primary outcomes listed in this review were studied in this study. The laronidase group achieved statistically significant improvements in per cent predicted forced vital capacity compared to placebo, MD 5.60 (95% confidence intervals 1.24 to 9.96) (low‐quality evidence) and in the six‐minute‐walk test (mean improvement of 38.1 metres in the laronidase group; P = 0.039, when using a prospectively planned analysis of covariance) (low‐quality evidence). The levels of urinary glycoaminoglycans were also significantly reduced (low‐quality evidence). In addition, there were improvements in hepatomegaly, sleep apnoea and hypopnoea. Laronidase antibodies were detected in nearly all participants in the treatment group with no apparent clinical effect and titres were reducing by the end of the study (very low‐quality evidence). Infusion‐related adverse reactions occurred in both groups but all were mild and none necessitated medical intervention or infusion cessation (low‐quality evidence). As assessed by questionnaires,changes in a 'Disability Index' after treatment were small and did not differ between groups (low‐quality evidence). There were no deaths in either group (low‐quality evidence). </p> </section> <section id="CD009354-sec-0007"> <h3 class="title" id="CD009354-sec-0007">Authors' conclusions</h3> <p>The current evidence demonstrates that laronidase is effective when compared to placebo in the treatment of mucopolysaccharidosis type I. The included study was comprehensive, with few participants and of low quality. The study included all of the key outcome measures we wished to look at. It demonstrated that laronidase is efficacious in relation to reducing biochemical parameters (reduced urine glycosaminoglycan excretion) and improved functional capacity as assessed by forced vital capacity and the six‐minute‐walk test. In addition glycosaminoglycan storage was reduced as ascertained by a reduction in liver volume. Laronidase appeared to be safe and, while antibodies were generated, these titres were reducing by the end of the study. More studies are required to determine long‐term effectiveness and safety and to assess the impact upon quality of life. Enzyme replacement therapy with laronidase can be used pre‐ and peri‐haemopoietic stem cell transplant, which is now the gold standard treatment in those individuals diagnosed under 2.5 years of age. We do not anticipate any further trials to be undertaken and therefore do not plan to update this review. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009354-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009354-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009354-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009354-abs-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009354-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009354-abs-0007">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009354-abs-0002" lang="en"> <h3>Enzyme replacement therapy with laronidase as a treatment for mucopolysaccharidosis type I (MPS I) </h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effect and safety of enzyme replacement therapy with laronidase for people with mucopolysaccharidosis type I (MPS I) who do not undergo haemopoietic stem cell transplantation and in people with MPS I who receive enzyme replacement therapy prior to haemopoietic stem cell transplantation. This is an updated version of the original Cochrane Review published in 2013 and previously updated in 2015. </p> <p><b>Background</b> </p> <p>Hurler syndrome or mucopolysaccharidosis type I is a rare genetic disorder that occurs when an enzyme that the body needs is missing or not working well enough. This leads to the build up of a number of complex molecules in certain cells and tissues. If untreated, this results in a classic picture of dwarfism, enlargement of body organs and a reduction in thinking ability. It occurs when a person inherits two copies of the defective gene (one from each parent) and is just as common in males as in females. It classically presents in infancy, however milder versions can present in adulthood. Enzyme replacement therapy with laronidase aims to replace the missing enzyme; however, given its high cost, it is essential to assess how effective and safe this treatment is. </p> <p><b>Search date</b> </p> <p>The evidence is current to: 30 January 2019.</p> <p><b>Study characteristics</b> </p> <p>One 26‐week randomised controlled study (45 participants) was included in the review. Participants were aged between six and 43 years old. The study was carried out in several centres around the world. Participants either received an intravenous infusion of laronidase 0.58 mg/kg or a placebo ('dummy' infusion). </p> <p><b>Key results</b> </p> <p>Current evidence is limited because we only found one randomised clinical trial in the medical literature, which did not include very many participants. Compared with placebo, enzyme replacement therapy improved lung function, the individuals’ ability to walk, reduced the excretion of abnormal glycosaminoglycans (a type of carbohydrate molecule) in the urine and also reduced the stopping of breathing related to sleep. Adverse reactions in relation to the infusions occurred in both groups but all were mild and none required medical intervention or for the infusions to be stopped. Enzyme replacement therapy can be used before and around the time of stem cell transplant, which is now the gold standard treatment for Hurler syndrome in individuals diagnosed before the age of two and a half years. More studies are needed to look at the long‐term effects of this treatment and also to see the effects on the quality of life of these individuals. We do not anticipate any further trials to be undertaken and therefore do not plan to update this review. </p> <p><b>Quality of the evidence</b> </p> <p>The included study was small and of low quality.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009354-sec-0077" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009354-sec-0077"></div> <h3 class="title" id="CD009354-sec-0078">Implications for practice</h3> <section id="CD009354-sec-0078"> <p>The randomised clinical study reviewed was of low quality and described all primary outcomes stated in the protocol and the majority of stated secondary outcomes. It has demonstrated that ERT with laronidase is effective in relation to functional capacity and efficacious in terms of liver volumes and urine GAG excretion in patients with MPS I when compared with placebo. It has also been demonstrated to be safe. However, HSCT should be the gold standard for those diagnosed with severe MPS I in the first 2 to 2.5 years of life. Although, ERT with laronidase can be useful for pre‐transplantation optimisation and in those with more attenuated disease. There does, however, remain uncertainty about the longer‐term outcomes of this lifelong and life‐limiting disease and studies looking at quality of life should be undertaken. </p> </section> <h3 class="title" id="CD009354-sec-0079">Implications for research</h3> <section id="CD009354-sec-0079"> <p>It is clear that ERT with laronidase is effective. Longitunidal reviews are now required to study the long‐term effects of laronidase and the effects in those patients commenced on treatment either earlier or later in life. The MPS I registry may prove a useful source of data but formal studies will be challenging to implement. In addition to gathering further data regarding long‐term outcomes, further research must also take place in regard to the effects of immunogenicity and the clinical consequences when significant antibody titres develop. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009354-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009354-sec-0008"></div> <div class="table" id="CD009354-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Laronidase compared with placebo for mucopolysaccharidosis type I</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults and children with mucopolysaccharidosis I </p> <p><b>Settings</b>: outpatient </p> <p><b>Intervention</b>: laronidase 0.58 mg / kg given weekly for 26 weeks </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Laronidase</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in urinary GAG excretion from baseline</p> <p>Follow‐up: 26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean increase of 47.3%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean reduction of 54.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N/A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt;0.001</p> <p>No standard deviations were given in the paper.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean percentage change from baseline in FVC (% predicted)</p> <p>Follow‐up: 26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean percentage change in FVC (% predicted) was ‐ 0.7 % (SD 5.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean percentage change was 5.6% higher (1.2 % higher to 9.96 % higher) in the laronidase group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in 6MWT (metres)</p> <p>Follow‐up: 26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in 6MWT was ‐18.4 metres (SD 67.5)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in 6MWT in the laronidase group was was 38.1 metres higher than the placebo group (1.7 metres lower to 77.9 metres higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our analysis shows a non significant difference between laronidase and placebo MD 38.10 (95% CI ‐1.68 to 77.88). </p> <p>The paper reports a significant difference favouring laronidase in a pre‐planned ANCOVA that took into account study centre, sex and baseline 6MWT, standing height and liver volume (P = 0.039). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infusion‐related reactions (number of participants with one or more reaction)</p> <p>Follow‐up: 26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>478 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>244 per 1000</b><br/>(72 to 817 per 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR</b> </p> <p><b>0.51</b> (0.15 to 1.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibody production: number of participants developing IgG antibodies</p> <p>Follow‐up: 26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Unable to calculate as assumed risk is zero</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR</b> </p> <p><b>385.4</b> (17.47 to 8500.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the laronidase group, 91% of patients (20 out of 22) developed IgG antibodies versus none in the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Changes in the Disability Index after treatment were "small and did not differ between groups" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No numerical results presented in the paper.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality: number of deaths</p> <p>Follow‐up: 26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There were no deaths in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>6MWT</b> : six‐minute walk test; <b>CI</b> : confidence interval; <b>FVC</b> : forced vital capacity; <b>GAG</b> : glycosaminoglycans; <b>OR</b>: odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded once due to an unclear risk of bias within the study from lack of information on process of randomisation and allocation concealment </p> <p>2. Downgraded once due to imprecision as the study had a small number of participants. There was no explanation of the sample size calculation and whether there were enough participants to show an effect. </p> <p>3. Downgraded twice due to imprecision as the study number was small and event rates were low. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009354-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009354-sec-0009"></div> <p>A glossary of terms can be found in the appendices (<a href="./appendices#CD009354-sec-0083">Appendix 1</a>). </p> <section id="CD009354-sec-0010"> <h3 class="title" id="CD009354-sec-0010">Description of the condition</h3> <p>Mucopolysaccharides, more commonly termed glycosaminoglycans (GAGs), are essential components of connective tissue providing structural support, as well as being involved in cellular regulation and communication. They are sugars composed of highly sulfated, alternating uronic acid and hexosamine residues, assembled into repeating units bound to specific core proteins within complex macromolecules called proteoglycans. Lysosomes are the cell organelles which are involved in the degradation of these large proteoglycans. The process of degradation requires several acid hydrolases. Deficiency of any one of these hydrolases results in a specific disease state. Mucopolysaccharidosis type I (MPS I) results when there is a deficiency of the enzyme alpha‐L‐iduronidase. This results in the inability of the lysosomes to breakdown two specific GAGs, dermatan sulphate and heparan sulphate. </p> <p>MPS I is an autosomal recessive disease with an incidence of 1 in 100,000 (<a href="./references#CD009354-bbs2-0021" title="MeiklePJ , HopwoodJJ , ClagueAE , CareyWF . Prevalance of lysosomal storage disorders. JAMA1999;281(3):249-54.">Meikle 1999</a>; <a href="./references#CD009354-bbs2-0024" title="NeufeldEF , MuenzerJ . The mucopolysaccharidoses. In: ScriverC , Beaudet, SlyW , et al, editors(s). The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw Hill, 2001:3421-52.">Neufeld 2001</a>) and is caused by mutations in the gene encoding alpha‐L‐iduronidase located on chromosome 4p16.3. The pathological MPS I alleles display significant ethnic variation. The common gene mutations in white populations are p.W402X and p.Q70X (<a href="./references#CD009354-bbs2-0026" title="TerlatoNJ , CoxGF . Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genetics in Medicine2003;5(4):286-94.">Terlato 2003</a>). The disorder can be detected on the screening of urine for urinary GAGs and if this is positive, confirmed by white cell enzyme analysis followed by mutation analysis. It is possible to perform antenatal testing on chorionic villus samples. </p> <p>Mucopolysaccharidosis type I can be classified as three clinical sub‐types; Hurler syndrome, Hurler‐Scheie syndrome and Scheie syndrome, with the scale of severity being such that Hurler syndrome is the most severe and Scheie syndrome the least severe. In cases of Hurler syndrome the child classically presents in the first year of life. The presentation can be varied and may take the form of cardiomyopathy, recurrent ear, nose and throat symptoms or recognition of coarse facies. Over the second and third years of life the other classic features of short stature and bony deformity, developmental delay, hepatosplenomegaly and corneal clouding develop. The clinical consequence is a chronic, progressive multi‐system disease, which if left untreated results in death by adolescence. At the opposite end of the spectrum, children with Scheie syndrome are intellectually normal and can have a normal life span; however, many will become disabled due to degenerative bony disease, corneal opacity and valvular heart disease. Many cases of MPS I are recorded on the MPS I Registry (<a href="./references#CD009354-bbs2-0022" title="Genzyme Corporation. MPS I Registry. www.lsdregistry.net/mpsiregistry/ (accessed 06 July 2011).">MPS I Register 2011</a>). This is a database which contains the clinical, investigation and treatment details of those patients registered. This database provides valuable information which can be used for evidence‐based research and practice. Data from the MPS I Registry show that more than half of the study population have Hurler syndrome with a quarter having Hurler‐Scheie syndrome and one tenth Scheie syndrome (<a href="./references#CD009354-bbs2-0016" title="D'AcoK , UnderhillL , RangachariL , ArnP , CoxGF , GiuglianiR , et al. Diagnosis and treatment in mucopolysaccharidosis I: findings from the MPS I Registry. European Journal of Pediarics2012;171(6):911-9.">D'Aco 2012</a>). Biochemically, the different phenotypes are indistinguishable and it is being increasingly acknowledged that MPS I represents a disease spectrum. </p> <p>Enzyme replacement therapy (ERT) either alone or in combination with haemopoietic stem cell transplantation (HSCT) is the mainstay of treatment. It has been shown that early treatment with ERT corresponds with a better outcome and that the use of HSCT prior to two years of age preserves cognition. In order to therefore maximise outcomes, the diagnosis of MPS I must be made in a timely manner. It is thus postulated that MPS I may be a candidate to be part of an expanded newborn screening schedule. It would be a suitable screening candidate as it can be detected on a blood spot sample, there is an effective treatment available and outcomes are much improved with early diagnosis. There would, however, be cost implications as ERT and HSCT are expensive therapies, and more research would be required into the effectiveness and long‐term outcomes. </p> </section> <section id="CD009354-sec-0011"> <h3 class="title" id="CD009354-sec-0011">Description of the intervention</h3> <p>In people with Hurler syndrome, ERT with laronidase, and in recent years laronidase in combination with HSCT in children under two years of age, has become the mainstay of treatment (<a href="./references#CD009354-bbs2-0023" title="MuenzerJ , WraithJE , Clarke LA and the International Consensus Panel on the Management and Treatment of Mucopolysaccharidosis I . Mucolpolysaccharidosis I: management and treatment guidelines. Pediatrics2009;123(1):19-29.">Muenzer 2009</a>).The latter is the preferred treatment regimen as transplantation provides an endogenous source of the missing enzyme, avoids the need for long‐term ERT and is better able to preserve cognition. The children typically receive laronidase between diagnosis and transplantation in order to maximise their pre‐transplantation condition and thus reduce their transplantation morbidity and mortality risks. The laronidase is then continued throughout conditioning and until donor engraftment has occurred. </p> <p>Laronidase (Aldurazyme<sup>®</sup>, produced by the Genzyme Corporation) is a specific recombinant alpha‐L‐iduronidase which received Food and Drugs Administration (FDA) approval as long‐term treatment for MPS I in 2003. It is a polymorphic variant of the human enzyme, alpha‐L‐iduronidase, with a molecular weight of 83 kD. It is produced by recombinant DNA technology in a Chinese hamster ovary cell line. The rationale of therapy is to provide exogenous enzyme for uptake into lysosomes and so to increase the catabolism of GAGs, and prevent their build up in tissues. The uptake of laronidase by cells into lysosomes is most likely mediated by the mannose‐6‐phosphate‐terminated oligosaccharide chains of laronidase binding to specific mannose‐6‐phosphate receptors. </p> <p>The recommended dose is 0.58 mg/kg administered on a weekly basis as an intravenous infusion. The pharmacodynamic effects have been assessed by analysing alterations in urinary GAG levels; laronidase was shown to significantly reduce these levels. The pharmacokinetics have been evaluated in patients six years and over. The mean plasma clearance ranged from 1.7 to 2.7 ml/min/kg and the mean half life ranged form 1.5 to 3.6 hours (these data come from published information on Aldurazyme<sup>®</sup> (<a href="./references#CD009354-bbs2-0017" title="Genzyme Therapeutics. Aldurazyme® (Laronidase). www.aldurazyme.com/pdf/az_us_hc_pi.pdf (accessed 25 September 2013).">Genzyme Therapeutics 2010</a>)). </p> <p>It has been observed that most patients develop antibodies by week 12 of the infusion. Individuals are therefore routinely pre‐medicated with antihistamines and anti‐pyretics one hour before the infusion commences. Side effects of laronidase include vomiting, nausea, arthralgia, diarrhoea, tachycardia, abdominal pain, hypertension, erythema, and cyanosis. There are no known drug interactions. Overall, the safety data have been encouraging (<a href="./references#CD009354-bbs2-0015" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40.">Clarke 2009</a>). </p> </section> <section id="CD009354-sec-0012"> <h3 class="title" id="CD009354-sec-0012">How the intervention might work</h3> <p>Gaucher disease, another inherited lysosomal storage disorder, is due to a deficiency of the enzyme glucocerebrosidase. The disorder is characterised by accumulation of the lipid glucocerebroside within the lysosomes of the monocyte‐macrophage system and leads to a multi‐system disorder with three distinct clinical phenotypes (<a href="./references#CD009354-bbs2-0014" title="CharrowJ , AnderssonHC , KaplanP , KolodnyEH , MistryP , PastoresG , et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Archives of Internal Medicine2000;160(18):2835-43.">Charrow 2000</a>). In 1991 targeted ERT in the form of Cerezyme<sup>®</sup> (imiglucerase for injection) was developed by the Genzyme Corporation in co‐operation with the National Institutes of Health (NIH). It was introduced into clinical practice in 1994 and it was seen to alleviate and even reverse many effects of Type 1 Gaucher disease (<a href="./references#CD009354-bbs2-0027" title="WeinrebNJ , CharrowJ , AnderssonHC , KaplanP , KolodnyEH , MistryP , et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. American Journal of Medicine2002;113(2):112-9.">Weinreb 2002</a>). It was therefore postulated that ERT might also work in MPS I and consequently laronidase was developed using a canine model. Laronidase has subsequently been used in humans to replace the missing alpha‐L‐iduronidase and so allow the lysosomes to breakdown dermatan sulphate and heparan sulphate. </p> </section> <section id="CD009354-sec-0013"> <h3 class="title" id="CD009354-sec-0013">Why it is important to do this review</h3> <p>Debate has arisen regarding the potential for newborn screening for MPS I, as it is believed that the earlier the condition is diagnosed the better the outcome. The aim of this review is to evaluate the effectiveness of ERT with laronidase for patients with MPS I. </p> <p>This review is important to conduct because:</p> <p> <ul id="CD009354-list-0001"> <li> <p>it will be the first systematic review of the use of laronidase in the management of MPS I; </p> </li> <li> <p>data collation will allow provision of an evidence‐based rationale for management recommendations; </p> </li> <li> <p>the systematic review will be of use to the MPS I Registry (<a href="./references#CD009354-bbs2-0022" title="Genzyme Corporation. MPS I Registry. www.lsdregistry.net/mpsiregistry/ (accessed 06 July 2011).">MPS I Register 2011</a>); </p> </li> <li> <p>it can be used in the debate surrounding newborn screening for MPS I.</p> </li> </ul> </p> <p>This is an update of a previously published version of this Cochrane Review (<a href="./references#CD009354-bbs2-0028" title="JamesonE , JonesS , WraithJE . Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I. Cochrane Database of Systematic Reviews2013, Issue 11. Art. No: CD009354. [DOI: 10.1002/14651858.CD009354.pub3]">Jameson 2013</a>). We do not anticipate any further trials to be undertaken and therefore do not plan to update this review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009354-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009354-sec-0014"></div> <p>The objectives of this review are to assess the effectiveness and safety of ERT with laronidase in the management of patients with: </p> <p> <ol id="CD009354-list-0002"> <li> <p>MPS I who do not undergo HSCT;</p> </li> <li> <p>MPS I who receive ERT prior to HSCT.</p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009354-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009354-sec-0015"></div> <section id="CD009354-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009354-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised and quasi‐randomised controlled studies.</p> </section> <section id="CD009354-sec-0018"> <h4 class="title">Types of participants</h4> <p>We aimed to study two groups of children:</p> <p> <ol id="CD009354-list-0003"> <li> <p>children aged 0 to 16 years with MPS I who receive only laronidase and do not undergo HSCT; </p> </li> <li> <p>children aged 0 to 16 years with MPS I who receive laronidase prior to undergoing HSCT. </p> </li> </ol> </p> <p>For future updates, if a study has a population of children from both the above two groups, authors will be contacted for individual data. These data will then be incorporated into the appropriate subgroups. The diagnosis in these children will have been established by accepted criteria of mutation analysis and enzyme concentration. </p> </section> <section id="CD009354-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Two intervention strategies compared to placebo:</p> <p> <ol id="CD009354-list-0004"> <li> <p>ERT with laronidase given for a period of at least one month when HSCT is not performed;</p> </li> <li> <p>ERT with laronidase given for a period of at least one month prior to HSCT.</p> </li> </ol> </p> </section> <section id="CD009354-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD009354-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD009354-list-0005"> <li> <p>Glycosaminoglycan (GAG) levels in urine</p> </li> <li> <p>Respiratory function as assessed by pulmonary function tests (e.g. forced expiratory volume at one second (FEV<sub>1</sub>), force vital capacity (FVC)) </p> </li> <li> <p>Endurance performance as assessed by endurance test in the form of the six‐minute walk test (6MWT) </p> </li> </ol> </p> </section> <section id="CD009354-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009354-list-0006"> <li> <p>Adverse effects of treatment, particularly incidence of allergic reactions to laronidase, increase in antibody titres and problems delivering the therapy </p> </li> <li> <p>Antibody production</p> </li> <li> <p>Echocardiographic findings (measures of systolic and diastolic function, hypertrophy and valve disease) </p> </li> <li> <p>Height</p> </li> <li> <p>Improvement in symptoms of nocturnal hypoventilation and sleep apnoea</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Mortality</p> </li> <li> <p>Effects on cognition (based on standard psychometric testing appropriate to age)</p> </li> <li> <p>Liver volume*</p> </li> </ol> </p> <p>* Post hoc change: this outcome has been added given that it demonstrates the reduction in GAG storage in the liver and is used clinically to check for recurrence of hepatomegaly if concerns are raised regarding the effectiveness of treatment. </p> </section> </section> </section> <section id="CD009354-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009354-sec-0024"> <h4 class="title">Electronic searches</h4> <p>Relevant studies were identified by searching the Inborn Errors of Metabolism Trials Register using the term: mucopolysaccharidosis. </p> <p>The Coagulopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library) and weekly searches of MEDLINE and the prospective handsearching of one journal ‐ <i>Haemophilia</i>. Unpublished work is identified by searching the abstract books of major conferences: the European Haematology Association conference; the American Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; the Congress of the World Federation of Hemophilia; the European Association for Haemophilia and Allied Disorders, the American Society of Gene and Cell Therapy and the International Society on Thrombosis and Haemostasis. For full details of all searching activities for the register, please see the relevant section of the Cochrane Cystic Fibrosis and Genetic Disorders Group's <a href="http://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of the most recent search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Inborn Errors of Metabolism Trials Register: 30 January 2019. </p> <p>We searched the following clinical trials registries: ClinicalTrials.gov; and the WHO ICTRP. For the full search strategies, please refer to the relevant appendix (<a href="./appendices#CD009354-sec-0084">Appendix 2</a>). Date of the most recent search: 01 October 2018. </p> <p>We also searched Embase and MEDLINE via OVID. For the full search strategies, please refer to the relevant appendix (<a href="./appendices#CD009354-sec-0085">Appendix 3</a>). No limitation was placed on the years searched. Date of the most recent search: 27 December 2015. </p> </section> <section id="CD009354-sec-0025"> <h4 class="title">Searching other resources</h4> <p>The reference lists of identified studies were reviewed with an aim to identify further studies not highlighted by the searches. </p> </section> </section> <section id="CD009354-sec-0026"> <h3 class="title" id="CD009354-sec-0026">Data collection and analysis</h3> <section id="CD009354-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two authors (SJ and EJ) independently assessed the titles and abstracts of the citations identified by the search strategy in order to select studies that fitted the inclusion criteria. There were no disagreements on selection. </p> </section> <section id="CD009354-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two authors (SJ and EJ) independently extracted data. There were no discrepancies or differences. The authors used a standard form to extract the following information: characteristics of the study; participants; interventions; and outcomes. The protocol had stated that outcomes would be assessed according to: </p> <p> <ol id="CD009354-list-0007"> <li> <p>those who had received ERT prior to HSCT and those who did not receive HSCT;</p> </li> <li> <p>those with central nervous system disease and those without;</p> </li> <li> <p>outcomes at selected time periods.</p> </li> </ol> </p> <p>We only identified one study and it did not cover these three subgroups. We report data from this study at 26 weeks of treatment. Analysis was undertaken using RevMan 5 (<a href="./references#CD009354-bbs2-0025" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.">RevMan 2011</a>). </p> </section> <section id="CD009354-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (EJ, SJ) assessed the risk of bias independently using the tool documented in section 8.5 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009354-bbs2-0018" title="HigginsJPT , AltmanDG , SterneJAC , on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org2011.">Higgins 20011a</a>). We assessed the following domains as having either a low, high, or unclear risk of bias: </p> <p> <ol id="CD009354-list-0008"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding (of participants, personnel and outcome assessors);</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting;</p> </li> <li> <p>other sources of bias.</p> </li> </ol> </p> <p>We have displayed the results of the risk of bias assessment in the 'Risk of bias' table in the section 'Characteristics of included studies' (<a href="./references#CD009354-sec-0095" title="">Characteristics of included studies</a>). </p> </section> <section id="CD009354-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>The authors calculated the pooled estimates of treatment effects across the included studies using pooled odds ratio (OR) for dichotomous data and pooled mean differences (MDs) for continuous data and the corresponding 95% confidence intervals (CIs). This would then have allowed calculation of the numbers needed to treat (NNT) and their 95% CIs from the pooled OR and its 95% CI for a specific baseline risk, which is the sum of all the events in the control groups (in all studies) divided by the total participant numbers in control groups in all studies (using an online calculator (<a href="./references#CD009354-bbs2-0013" title="Visual Rx. Online NNT Calculator. www.nntonline.net/ (accessed 01 June 2013).">Cates 2003</a>)). However, this was not possible due to the small numbers of participants. </p> <p>As per our protocol, we were able to present data at one of our pre‐specified time‐periods, i.e. at six months. For future updates, if we are able to include more studies, we plan to group outcomes into the following time periods, e.g. at six months, at one year, at five years, at 10 years. </p> </section> <section id="CD009354-sec-0031"> <h4 class="title">Dealing with missing data</h4> <p>The authors reported dropout rates in the 'Characteristics of included studies' table (<a href="./references#CD009354-sec-0095" title="">Characteristics of included studies</a>). </p> </section> <section id="CD009354-sec-0032"> <h4 class="title">Assessment of heterogeneity</h4> <p>We were only able to include one study and therefore we did not evaluate heterogeneity. If we are able to include further studies when we update this review, we will calculate inconsistencies based on the I² statistic. This describes the percentage of variability in effect estimates that is due to heterogeneity rather than sampling error (<a href="./references#CD009354-bbs2-0019" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistencies in meta-analyses. 2003 BMJ;327(7414):557-60.">Higgins 2003</a>). We will interpret the I² statistic based on the guidance for thresholds outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions.</i> This means that we will regard below 50% as low heterogeneity, between 50% and 75% as moderate heterogeneity and over 75% as substantial heterogeneity (<a href="./references#CD009354-bbs2-0020" title="DeeksJJ , HigginsJPT , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org2011.">Higgins 2011b</a>). </p> </section> <section id="CD009354-sec-0033"> <h4 class="title">Assessment of reporting biases</h4> <p>If we identify further studies for future updates of this review, such that there are at least 10 included studies, we will ascertain publication bias using a funnel plot. An asymmetrical funnel plot, will lead to an exploration for alternative causes in addition to publication bias. </p> </section> <section id="CD009354-sec-0034"> <h4 class="title">Data synthesis</h4> <section id="CD009354-sec-0035"> <h5 class="title">Qualitative</h5> <p>The authors produced qualitative information relative to methods, risk of bias, description of participants and outcome measures and have documented this information in the table of 'Characteristics of included studies' (<a href="./references#CD009354-sec-0095" title="">Characteristics of included studies</a>). </p> </section> <section id="CD009354-sec-0036"> <h5 class="title">Quantative</h5> <p>The authors analysed dichotomous variables using the OR and 95% CIs and continuous variables using the MD and 95% CIs. </p> <p>If we identify any additional studies in future updates, we will incorporate these using either a fixed‐effect model in the absence of moderate or substantial heterogeneity, or a random‐effects model if we identify moderate or substantial heterogeneity as described above. </p> </section> </section> <section id="CD009354-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We stated in the protocol that outcomes would be assessed according to:</p> <p> <ol id="CD009354-list-0009"> <li> <p>those who had received ERT prior to HSCT and those who did not receive HSCT;</p> </li> <li> <p>those with central nervous system disease and those without;</p> </li> <li> <p>outcomes at selected time periods.</p> </li> </ol> </p> <p>However, given there was only one eligible study (which did not make these differentiations), we were not able to carry out any such subgroup analyses. </p> </section> <section id="CD009354-sec-0038"> <h4 class="title">Sensitivity analysis</h4> <p>We only included one study in the review, so we did not perform any sensitivity analysis. However, if in future updates there are sufficient comparable studies to allow, we plan to perform a sensitivity analysis excluding those studies with a high risk of bias for allocation concealment. </p> </section> <section id="CD009354-sec-0039"> <h4 class="title">Summary of findings tables and quality of the evidence (GRADE)</h4> <p>In a post hoc change in line with current Cochrane guidance, at the 2019 update we added a summary of findings table for each comparison presented in the review (<a href="./full#CD009354-tbl-0001">summary of findings Table 1</a>). We selected the following outcomes to report (chosen based on relevance to clinicians and consumers). </p> <p> <ol id="CD009354-list-0010"> <li> <p>Glycosaminoglycan (GAG) levels in urine</p> </li> <li> <p>Respiratory function as assessed by pulmonary function tests (e.g. forced expiratory volume at one second (FEV<sub>1</sub>), force vital capacity (FVC)) </p> </li> <li> <p>Endurance performance as assessed by endurance test in the form of the six‐minute walk test (6MWT) </p> </li> <li> <p>Adverse effects of treatment, particularly incidence of allergic reactions to laronidase, increase in antibody titres and problems delivering the therapy </p> </li> <li> <p>Antibody production</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Mortality</p> </li> </ol> </p> <p>We determined the quality of the evidence using the GRADE approach; and downgraded evidence in the presence of a high risk of bias in at least one trial, indirectness of the evidence, unexplained heterogeneity or inconsistency, imprecision of results, high probability of publication bias. We downgraded evidence by one level if they considered the limitation to be serious and by two levels if very serious. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009354-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009354-sec-0040"></div> <section id="CD009354-sec-0041"> <h3 class="title">Description of studies</h3> <section id="CD009354-sec-0042"> <h4 class="title">Results of the search</h4> <p>There were 204 records identified by all of the searches:</p> <p> <ul id="CD009354-list-0011"> <li> <p>MEDLINE (via OVID): 154 references;</p> </li> <li> <p>Cochrane Cystic Fibrosis and Genetic Disorders Group’s Trials Register: 29 references;</p> </li> <li> <p>Embase: 0 references.</p> </li> <li> <p>ClinicalTrials.gov and the WHO ICTRP: 21 references .</p> </li> </ul> </p> <p>The authors reviewed the titles and abstracts. Five duplicates were removed, a total of 180 references were excluded based on title alone. A further 19 references were regarded as potentially relevant and were selected for further review. Of those selected, the bibliographical references were reviewed looking for further potentially eligible studies, but none were found. After further review of these 11 studies (19 references), nine were excluded from further analysis. Full text copies of the two remaining studies (10 references) were obtained and were then subjected to further assessment. Following the verification of two whole studies, only one (six references) fulfilled all the inclusion criteria of this review (<a href="./references#CD009354-bbs2-0001" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40. ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase 3 extension study of aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I). Journal of Inherited Metabolic Disease2006;29(Suppl 1):28. [ABSTRACT NO.: WS-9-4] [CENTRAL: 1000736] ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase III extension study of aldurazyme(laronidase) in mucopolysaccharidosis I. Clinical Therapeutics2007;29(Suppl C):S111. NCT00912925. Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I. clinicaltrials.gov/ct2/show/NCT00912925 (first posted 03 June 2009). WraithJE , ClarkeLA , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics2004;144(5):581-8. WraithJE , MuenzerJ , KolodnyEH , PastoresGM , BeckM , ClarkeLA . Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 96-week extension data. Journal of Inherited Metabolic Disease2005;28(Suppl 1):182. [ABSTRACT NO.: 360-P] [CENTRAL: 1000735] ">Wraith 2004</a>) and one (four references) was excluded (<a href="./references#CD009354-bbs2-0004" title="GiuglianiR , RojasVM , MartinsAM , ValadaresER , ClarkeJTR , GoesJEC , et al. A dose-optimisation trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Molecular Genetics and Metabolism2009;96(1):13-9. ">Giugliani 2008</a>). Thus, one study (six references) was included and 10 studies (13 references) were excluded (see '<a href="#CD009354-sec-0047">Excluded studies</a>' section). </p> </section> <section id="CD009354-sec-0043"> <h4 class="title">Included studies</h4> <p>The included study was a multicentre, multinational, double‐blind, randomised, placebo‐controlled, 26‐week, phase III study of the efficacy and safety of laronidase 0.58 mg/kg (100 units/kg) administered weekly in patients with MPS I (<a href="./references#CD009354-bbs2-0001" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40. ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase 3 extension study of aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I). Journal of Inherited Metabolic Disease2006;29(Suppl 1):28. [ABSTRACT NO.: WS-9-4] [CENTRAL: 1000736] ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase III extension study of aldurazyme(laronidase) in mucopolysaccharidosis I. Clinical Therapeutics2007;29(Suppl C):S111. NCT00912925. Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I. clinicaltrials.gov/ct2/show/NCT00912925 (first posted 03 June 2009). WraithJE , ClarkeLA , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics2004;144(5):581-8. WraithJE , MuenzerJ , KolodnyEH , PastoresGM , BeckM , ClarkeLA . Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 96-week extension data. Journal of Inherited Metabolic Disease2005;28(Suppl 1):182. [ABSTRACT NO.: 360-P] [CENTRAL: 1000735] ">Wraith 2004</a>). </p> <section id="CD009354-sec-0044"> <h5 class="title">Participants</h5> <p>The study included 45 patients with MPS I. The biochemical evidence of MPS I was a documented deficiency of iduronidase activity of less than 10% of normal in addition to measurable clinical disease. Included patients had to be at least five years old, be able to perform a reproducible FVC manoeuvre that was less than or equal to 80% of normal based on the Polgar formula, be able to stand independently and be able to walk a minimum of five metres in six minutes. Exclusion criteria were a previous tracheostomy or bone marrow transplant; pregnancy or lactation; administration of any investigational drug within 30 days before enrolment; a medical condition or other circumstance that could interfere with compliance or a known hypersensitivity to laronidase, components of laronidase or the placebo solution. The mean age of the patients in the laronidase arm was 15.6 years (range 7 to 43 years) and in the placebo arm 15.4 years (range 6 to 39 years). The laronidase group consisted of 11 males and 11 females; the placebo group 11 males and 12 females. </p> </section> <section id="CD009354-sec-0045"> <h5 class="title">Interventions</h5> <p>The 45 patients were randomly assigned to either weekly intravenous laronidase 100 U/kg (0.58 mg/kg) in a solution of sodium phosphate, sodium chloride and polysorbate‐80 or to the same solution but without the laronidase. All treatments were diluted in 0.1% human albumin in normal saline and given over four hours. All patients were pre‐medicated with an anti‐pyretic and an antihistamine. </p> </section> <section id="CD009354-sec-0046"> <h5 class="title">Outcomes</h5> <p>The primary efficacy outcomes of the one included study compared the median change from baseline to week 26 between the treatment and placebo groups in percentage of predicted normal FVC and in a 6MWT distance. The FVC measurements were obtained by spirometry in accordance with the American Thoracic Society guidelines (<a href="./references#CD009354-bbs2-0012" title="American Thoracic Society. Standardization of spirometry, 1994 update. American Thoracic Society. American Journal of Respiratory and Critical Care Medicine1995;152:1107-36.">ATS 1995</a>). The secondary outcomes were: adverse events; antibody production; nocturnal hypoventilation and sleep apnoea; quality of life; and mortality. Again, results were presented as change from baseline. </p> </section> </section> <section id="CD009354-sec-0047"> <h4 class="title">Excluded studies</h4> <p>A total of 10 studies were excluded (<a href="./references#CD009354-bbs2-0002" title="ChenA , DicksonP , ShapiroE , HarmatzP . A study of intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis I. Molecular Genetics and Metabolism2015;114(2):S30. [ABSTRACT NO.: 47] [CENTRAL: 1077599] [EMBASE: 71804588]ChenA , DicksonP , ShapiroE , HarmatzP . Intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis type I. Molecular Genetics and Metabolism2014;111(2):S30. [ABSTRACT NO.: 42] [CENTRAL: 1073795] [EMBASE: 71805025]ChenA , DicksonP , ShapiroE , RovaiL , Kan S-H. A study of intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis I. Molecular Genetics and Metabolism2013;108(2):S29. [ABSTRACT NO.: 38] [CENTRAL: 1073858] [EMBASE: 71805301]ChenA , NestrasilI , ShapiroE , EisengartJ , MaarupT , PolgreenL , et al. A randomized open-label clinical trial of intrathecal recombinant human alpha-L-iduronidase for cognitive decline in mucopolysaccharidosis type i. Molecular Genetics and Metabolism2017;(1-2):S35. ">Chen 2015</a>; <a href="./references#CD009354-bbs2-0003" title="deRueMH , BoelensJJ , DasAM , JonesSA , van derLeddJH , MahlaouiN , et al. Enzyme replacement therapy and / or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet Journal of Rare Disease2011;6(55):1-9. ">de Rue 2011</a>; <a href="./references#CD009354-bbs2-0004" title="GiuglianiR , RojasVM , MartinsAM , ValadaresER , ClarkeJTR , GoesJEC , et al. A dose-optimisation trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Molecular Genetics and Metabolism2009;96(1):13-9. ">Giugliani 2008</a>; <a href="./references#CD009354-bbs2-0005" title="GrewalSS , WynnR , AbdenurJE , BurtonBK , GharibM , HaaseC , et al. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genetics in Medicine2005;7(2):143-6. ">Grewal 2005</a>; <a href="./references#CD009354-bbs2-0006" title="KakkisED , MuenzerJ , TillerGE , WaberL , BelmontJ , PassageM , et al. Enzyme-replacement therapy in mucopolysaccharidosis I. New England Journal of Medicine2001;344(3):182-8. ">Kakkis 2001a</a>; <a href="./references#CD009354-bbs2-0007" title="KakkisE . Enzyme replacement therapy for the mucopolysaccharidoses. Journal of Inherited Metabolic Disease2001;14(7):776. [CENTRAL: 461031] ">Kakkis 2001b</a>; <a href="./references#CD009354-bbs2-0008" title="PitzS , OgunO , BajboujM , ArashL , Schulze-FrenkingG , BeckM . Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy. Archives of Ophthalmology2007;125(10):1353-6. ">Pitz 2007</a>; <a href="./references#CD009354-bbs2-0009" title="SalehpourS , AlaeiMR , VakiliR , RezaeiAR , MomtazmaneshN , TonekaboniSH , et al. Intrathecal alpha-L-iduronidase protects from or improves neurodevelopmental decline and neuroimaging abnormalities of children with MPS I below 6 years. Journal of Inherited Metabolic Disease2015;38(Issue 1 Suppl). [ABSTRACT NO.: O-049] [CENTRAL: 1089493] ">Salehpour 2015</a>; <a href="./references#CD009354-bbs2-0010" title="Wraith JE,  BeckM ,  LaneR ,  van der PloegA ,  ShapiroE ,  XueY ,  et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics2007;120(1):e37-46. ">Wraith 2007</a>; <a href="./references#CD009354-bbs2-0011" title="WynnRF , MercerJ , Page, J, CarrTF , JonesS , WraithJE . Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients. Journal of Pediatrics2009;154(1):135-9. ">Wynn 2008</a>). One study was a phase I study with no placebo arm (<a href="./references#CD009354-bbs2-0006" title="KakkisED , MuenzerJ , TillerGE , WaberL , BelmontJ , PassageM , et al. Enzyme-replacement therapy in mucopolysaccharidosis I. New England Journal of Medicine2001;344(3):182-8. ">Kakkis 2001a</a>); one was a consensus report (<a href="./references#CD009354-bbs2-0003" title="deRueMH , BoelensJJ , DasAM , JonesSA , van derLeddJH , MahlaouiN , et al. Enzyme replacement therapy and / or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet Journal of Rare Disease2011;6(55):1-9. ">de Rue 2011</a>); two were on intrathecal ERT (<a href="./references#CD009354-bbs2-0002" title="ChenA , DicksonP , ShapiroE , HarmatzP . A study of intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis I. Molecular Genetics and Metabolism2015;114(2):S30. [ABSTRACT NO.: 47] [CENTRAL: 1077599] [EMBASE: 71804588]ChenA , DicksonP , ShapiroE , HarmatzP . Intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis type I. Molecular Genetics and Metabolism2014;111(2):S30. [ABSTRACT NO.: 42] [CENTRAL: 1073795] [EMBASE: 71805025]ChenA , DicksonP , ShapiroE , RovaiL , Kan S-H. A study of intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis I. Molecular Genetics and Metabolism2013;108(2):S29. [ABSTRACT NO.: 38] [CENTRAL: 1073858] [EMBASE: 71805301]ChenA , NestrasilI , ShapiroE , EisengartJ , MaarupT , PolgreenL , et al. A randomized open-label clinical trial of intrathecal recombinant human alpha-L-iduronidase for cognitive decline in mucopolysaccharidosis type i. Molecular Genetics and Metabolism2017;(1-2):S35. ">Chen 2015</a>; <a href="./references#CD009354-bbs2-0009" title="SalehpourS , AlaeiMR , VakiliR , RezaeiAR , MomtazmaneshN , TonekaboniSH , et al. Intrathecal alpha-L-iduronidase protects from or improves neurodevelopmental decline and neuroimaging abnormalities of children with MPS I below 6 years. Journal of Inherited Metabolic Disease2015;38(Issue 1 Suppl). [ABSTRACT NO.: O-049] [CENTRAL: 1089493] ">Salehpour 2015</a>), one was concerned with dose optimisation (<a href="./references#CD009354-bbs2-0004" title="GiuglianiR , RojasVM , MartinsAM , ValadaresER , ClarkeJTR , GoesJEC , et al. A dose-optimisation trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Molecular Genetics and Metabolism2009;96(1):13-9. ">Giugliani 2008</a>); one was concerned with safety, pharmacokinetics and efficacy (<a href="./references#CD009354-bbs2-0010" title="Wraith JE,  BeckM ,  LaneR ,  van der PloegA ,  ShapiroE ,  XueY ,  et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics2007;120(1):e37-46. ">Wraith 2007</a>); one was an overview of ERT (<a href="./references#CD009354-bbs2-0007" title="KakkisE . Enzyme replacement therapy for the mucopolysaccharidoses. Journal of Inherited Metabolic Disease2001;14(7):776. [CENTRAL: 461031] ">Kakkis 2001b</a>); and one because it did not cover the described outcomes, only commenting on an ophthalmology outcome (<a href="./references#CD009354-bbs2-0008" title="PitzS , OgunO , BajboujM , ArashL , Schulze-FrenkingG , BeckM . Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy. Archives of Ophthalmology2007;125(10):1353-6. ">Pitz 2007</a>). A further two were excluded because they were narrative reviews of the effects of laronidase prior to bone marrow transplant (<a href="./references#CD009354-bbs2-0005" title="GrewalSS , WynnR , AbdenurJE , BurtonBK , GharibM , HaaseC , et al. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genetics in Medicine2005;7(2):143-6. ">Grewal 2005</a>; <a href="./references#CD009354-bbs2-0011" title="WynnRF , MercerJ , Page, J, CarrTF , JonesS , WraithJE . Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients. Journal of Pediatrics2009;154(1):135-9. ">Wynn 2008</a>). For further information, please refer to the 'Characteristics of excluded studies' table (<a href="./references#CD009354-sec-0096" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD009354-sec-0048"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD009354-sec-0049"> <h4 class="title">Allocation</h4> <section id="CD009354-sec-0050"> <h5 class="title">Generation of the randomisation sequence</h5> <p>Generation of the randomisation sequence was not clearly described in the included study and therefore assessed as having an unclear risk of bias (<a href="./references#CD009354-bbs2-0001" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40. ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase 3 extension study of aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I). Journal of Inherited Metabolic Disease2006;29(Suppl 1):28. [ABSTRACT NO.: WS-9-4] [CENTRAL: 1000736] ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase III extension study of aldurazyme(laronidase) in mucopolysaccharidosis I. Clinical Therapeutics2007;29(Suppl C):S111. NCT00912925. Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I. clinicaltrials.gov/ct2/show/NCT00912925 (first posted 03 June 2009). WraithJE , ClarkeLA , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics2004;144(5):581-8. WraithJE , MuenzerJ , KolodnyEH , PastoresGM , BeckM , ClarkeLA . Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 96-week extension data. Journal of Inherited Metabolic Disease2005;28(Suppl 1):182. [ABSTRACT NO.: 360-P] [CENTRAL: 1000735] ">Wraith 2004</a>). </p> </section> <section id="CD009354-sec-0051"> <h5 class="title">Allocation concealment</h5> <p>Likewise, allocation concealment was not discussed in the study, which is also categorised as having an unclear risk of bias (<a href="./references#CD009354-bbs2-0001" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40. ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase 3 extension study of aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I). Journal of Inherited Metabolic Disease2006;29(Suppl 1):28. [ABSTRACT NO.: WS-9-4] [CENTRAL: 1000736] ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase III extension study of aldurazyme(laronidase) in mucopolysaccharidosis I. Clinical Therapeutics2007;29(Suppl C):S111. NCT00912925. Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I. clinicaltrials.gov/ct2/show/NCT00912925 (first posted 03 June 2009). WraithJE , ClarkeLA , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics2004;144(5):581-8. WraithJE , MuenzerJ , KolodnyEH , PastoresGM , BeckM , ClarkeLA . Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 96-week extension data. Journal of Inherited Metabolic Disease2005;28(Suppl 1):182. [ABSTRACT NO.: 360-P] [CENTRAL: 1000735] ">Wraith 2004</a>). </p> </section> </section> <section id="CD009354-sec-0052"> <h4 class="title">Blinding</h4> <p>The study was double‐blinded, and all patients received weekly intravenous infusions (<a href="./references#CD009354-bbs2-0001" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40. ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase 3 extension study of aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I). Journal of Inherited Metabolic Disease2006;29(Suppl 1):28. [ABSTRACT NO.: WS-9-4] [CENTRAL: 1000736] ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase III extension study of aldurazyme(laronidase) in mucopolysaccharidosis I. Clinical Therapeutics2007;29(Suppl C):S111. NCT00912925. Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I. clinicaltrials.gov/ct2/show/NCT00912925 (first posted 03 June 2009). WraithJE , ClarkeLA , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics2004;144(5):581-8. WraithJE , MuenzerJ , KolodnyEH , PastoresGM , BeckM , ClarkeLA . Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 96-week extension data. Journal of Inherited Metabolic Disease2005;28(Suppl 1):182. [ABSTRACT NO.: 360-P] [CENTRAL: 1000735] ">Wraith 2004</a>). The primary outcome assessments were conducted by the responsible medical teams. We therefore judged the study to have a low risk of bias for blinding of participants, clinicians and outcome assessors. </p> </section> <section id="CD009354-sec-0053"> <h4 class="title">Incomplete outcome data</h4> <p>All participants completed the study (<a href="./references#CD009354-bbs2-0001" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40. ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase 3 extension study of aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I). Journal of Inherited Metabolic Disease2006;29(Suppl 1):28. [ABSTRACT NO.: WS-9-4] [CENTRAL: 1000736] ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase III extension study of aldurazyme(laronidase) in mucopolysaccharidosis I. Clinical Therapeutics2007;29(Suppl C):S111. NCT00912925. Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I. clinicaltrials.gov/ct2/show/NCT00912925 (first posted 03 June 2009). WraithJE , ClarkeLA , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics2004;144(5):581-8. WraithJE , MuenzerJ , KolodnyEH , PastoresGM , BeckM , ClarkeLA . Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 96-week extension data. Journal of Inherited Metabolic Disease2005;28(Suppl 1):182. [ABSTRACT NO.: 360-P] [CENTRAL: 1000735] ">Wraith 2004</a>). There were no deaths. We have therefore assessed this domain as having a low risk of bias. </p> </section> <section id="CD009354-sec-0054"> <h4 class="title">Selective reporting</h4> <p>All important clinical outcomes were evaluated (<a href="./references#CD009354-bbs2-0001" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40. ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase 3 extension study of aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I). Journal of Inherited Metabolic Disease2006;29(Suppl 1):28. [ABSTRACT NO.: WS-9-4] [CENTRAL: 1000736] ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase III extension study of aldurazyme(laronidase) in mucopolysaccharidosis I. Clinical Therapeutics2007;29(Suppl C):S111. NCT00912925. Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I. clinicaltrials.gov/ct2/show/NCT00912925 (first posted 03 June 2009). WraithJE , ClarkeLA , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics2004;144(5):581-8. WraithJE , MuenzerJ , KolodnyEH , PastoresGM , BeckM , ClarkeLA . Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 96-week extension data. Journal of Inherited Metabolic Disease2005;28(Suppl 1):182. [ABSTRACT NO.: 360-P] [CENTRAL: 1000735] ">Wraith 2004</a>). We therefore assessed this domain as having a low risk of bias. </p> </section> <section id="CD009354-sec-0055"> <h4 class="title">Other potential sources of bias</h4> <p>We believe that the study was free of other problems that could put it at a high risk of bias (<a href="./references#CD009354-bbs2-0001" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40. ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase 3 extension study of aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I). Journal of Inherited Metabolic Disease2006;29(Suppl 1):28. [ABSTRACT NO.: WS-9-4] [CENTRAL: 1000736] ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase III extension study of aldurazyme(laronidase) in mucopolysaccharidosis I. Clinical Therapeutics2007;29(Suppl C):S111. NCT00912925. Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I. clinicaltrials.gov/ct2/show/NCT00912925 (first posted 03 June 2009). WraithJE , ClarkeLA , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics2004;144(5):581-8. WraithJE , MuenzerJ , KolodnyEH , PastoresGM , BeckM , ClarkeLA . Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 96-week extension data. Journal of Inherited Metabolic Disease2005;28(Suppl 1):182. [ABSTRACT NO.: 360-P] [CENTRAL: 1000735] ">Wraith 2004</a>). </p> </section> </section> <section id="CD009354-sec-0056"> <h3 class="title" id="CD009354-sec-0056">Effects of interventions</h3> <p>See: <a href="./full#CD009354-tbl-0001"><b>Summary of findings 1</b> Summary of findings</a> </p> <p>In the included study, patients were randomised into two groups; laronidase 0.58 mg/kg (100 IU/Kg) weekly or placebo weekly (<a href="./references#CD009354-bbs2-0001" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40. ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase 3 extension study of aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I). Journal of Inherited Metabolic Disease2006;29(Suppl 1):28. [ABSTRACT NO.: WS-9-4] [CENTRAL: 1000736] ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase III extension study of aldurazyme(laronidase) in mucopolysaccharidosis I. Clinical Therapeutics2007;29(Suppl C):S111. NCT00912925. Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I. clinicaltrials.gov/ct2/show/NCT00912925 (first posted 03 June 2009). WraithJE , ClarkeLA , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics2004;144(5):581-8. WraithJE , MuenzerJ , KolodnyEH , PastoresGM , BeckM , ClarkeLA . Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 96-week extension data. Journal of Inherited Metabolic Disease2005;28(Suppl 1):182. [ABSTRACT NO.: 360-P] [CENTRAL: 1000735] ">Wraith 2004</a>).  </p> <p>The quality of the evidence has been graded for those outcomes included in the summary of findings table. For the definitions of these gradings, please refer to the summary of findings tables (<a href="./full#CD009354-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD009354-sec-0057"> <h4 class="title">Primary outcomes</h4> <section id="CD009354-sec-0058"> <h5 class="title">1. Glycosaminoglycan levels in urine</h5> <p>Urinary GAG excretion rapidly and significantly decreased in the laronidase group (<a href="./references#CD009354-bbs2-0001" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40. ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase 3 extension study of aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I). Journal of Inherited Metabolic Disease2006;29(Suppl 1):28. [ABSTRACT NO.: WS-9-4] [CENTRAL: 1000736] ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase III extension study of aldurazyme(laronidase) in mucopolysaccharidosis I. Clinical Therapeutics2007;29(Suppl C):S111. NCT00912925. Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I. clinicaltrials.gov/ct2/show/NCT00912925 (first posted 03 June 2009). WraithJE , ClarkeLA , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics2004;144(5):581-8. WraithJE , MuenzerJ , KolodnyEH , PastoresGM , BeckM , ClarkeLA . Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 96-week extension data. Journal of Inherited Metabolic Disease2005;28(Suppl 1):182. [ABSTRACT NO.: 360-P] [CENTRAL: 1000735] ">Wraith 2004</a>). By week 26 the laronidase group showed a mean reduction of 54.1% in urinary GAG excretion compared to a mean increase of 47.3% in the placebo group (P = &lt; 0.001) (low‐quality evidence) (<a href="./references#CD009354-fig-0001" title="">Analysis 1.1</a>); standard deviations (SDs) were not included in the paper. In the treatment group, mean reduction to levels approaching the upper limit of normal occurred by week four and were maintained throughout treatment. </p> </section> <section id="CD009354-sec-0059"> <h5 class="title">2. Respiratory function</h5> <p>After 26 weeks of treatment patients receiving laronidase showed a mean 5.6 percentage point increase in per cent of predicted normal FVC compared with the placebo group (median 3.0; P = 0.009), MD 5.60 (95% CI 1.24 to 9.96) (low‐quality evidence) (<a href="./references#CD009354-fig-0002" title="">Analysis 1.2</a>). The improvement remained significant when per cent of predicted normal FVC was calculated by using each patient’s current rather than baseline height (mean 4.3 and median 22 percentage point difference, P = 0.022). The treatment effect was maintained (P = 0.007) when study centre and baseline FVC, apnoea‐hypopnoea index (AHI), total lung capacity, liver volume and urinary GAG level were taken into account by an analysis of covariance (ANCOVA). </p> </section> <section id="CD009354-sec-0060"> <h5 class="title">3. Endurance performance as assessed by 6MWT</h5> <p>After 26 weeks treatment the laronidase group showed a mean 38.1 metre increase in 6MWT compared with the placebo group (median 38.5, P = 0.066). When the data where entered into the meta‐analysis, there was no significant difference observed between the laronidase and the placebo groups, MD 38.10 (95% CI ‐1.68 to 77.88) (low‐quality evidence) (<a href="./references#CD009354-fig-0003" title="">Analysis 1.3</a>). However, the effect achieves statistical significance (P = 0.039) in a prospectively planned ANCOVA that took into account study centre, sex and baseline 6MWT, standing height and liver volume. The original paper reports that 6MWT was higher in the laronidase group at each time point compared to placebo (means only estimable on a graph and no SDs provided). </p> </section> </section> <section id="CD009354-sec-0061"> <h4 class="title">Secondary outcomes</h4> <section id="CD009354-sec-0062"> <h5 class="title">1. Adverse effects of treatment, particularly incidence of allergic reactions to laronidase, increase in antibody titres and problems delivering the therapy </h5> <p>Except for one patient in the laronidase group, all patients had at least one adverse event, the majority being associated with the underlying MPS I. Infusion‐related reactions consisting mainly of flushing, fever, headache and rash had a similar incidence in both groups, 32% versus 48% in the laronidase versus placebo groups respectively. Most were mild and none required medical intervention or interruption of infusions, there was no significant difference between the laronidase and the placebo groups, OR 0.51 (95% CI 0.15 to 1.71) (low‐quality evidence) (<a href="./references#CD009354-fig-0004" title="">Analysis 1.4</a>).  </p> </section> <section id="CD009354-sec-0063"> <h5 class="title">2. Antibody production</h5> <p>In the laronidase group, 91% of patients (20 out of 22) developed IgG antibodies. Mean (SD) time to seroconversion was 52.6 (24.1) days (range 20 to 106). By study end, most antibody levels were declining (very low‐quality evidence). </p> </section> <section id="CD009354-sec-0064"> <h5 class="title">3. Echocardiographic findings</h5> <p>No measures of systolic and diastolic function, hypertrophy and valve disease were reported on in the included study (<a href="./references#CD009354-bbs2-0001" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40. ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase 3 extension study of aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I). Journal of Inherited Metabolic Disease2006;29(Suppl 1):28. [ABSTRACT NO.: WS-9-4] [CENTRAL: 1000736] ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase III extension study of aldurazyme(laronidase) in mucopolysaccharidosis I. Clinical Therapeutics2007;29(Suppl C):S111. NCT00912925. Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I. clinicaltrials.gov/ct2/show/NCT00912925 (first posted 03 June 2009). WraithJE , ClarkeLA , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics2004;144(5):581-8. WraithJE , MuenzerJ , KolodnyEH , PastoresGM , BeckM , ClarkeLA . Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 96-week extension data. Journal of Inherited Metabolic Disease2005;28(Suppl 1):182. [ABSTRACT NO.: 360-P] [CENTRAL: 1000735] ">Wraith 2004</a>). </p> </section> <section id="CD009354-sec-0065"> <h5 class="title">4. Height</h5> <p>This outcome was not reported on in the included study (<a href="./references#CD009354-bbs2-0001" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40. ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase 3 extension study of aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I). Journal of Inherited Metabolic Disease2006;29(Suppl 1):28. [ABSTRACT NO.: WS-9-4] [CENTRAL: 1000736] ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase III extension study of aldurazyme(laronidase) in mucopolysaccharidosis I. Clinical Therapeutics2007;29(Suppl C):S111. NCT00912925. Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I. clinicaltrials.gov/ct2/show/NCT00912925 (first posted 03 June 2009). WraithJE , ClarkeLA , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics2004;144(5):581-8. WraithJE , MuenzerJ , KolodnyEH , PastoresGM , BeckM , ClarkeLA . Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 96-week extension data. Journal of Inherited Metabolic Disease2005;28(Suppl 1):182. [ABSTRACT NO.: 360-P] [CENTRAL: 1000735] ">Wraith 2004</a>).  </p> </section> <section id="CD009354-sec-0066"> <h5 class="title">5. Improvement in symptoms of nocturnal hypoventilation and sleep apnoea</h5> <p>After 26 weeks treatment the mean AHI decreased by 3.6 events per hour in the laronidase group compared with the placebo group (P = 0.145). Since nearly half the group had normal baseline sleep studies, a <i>post hoc</i> subgroup analysis was performed on patients whose baseline AHI suggested sleep apnoea. This showed that the laronidase group (n = 10) had a mean decrease of six events per hour of sleep during the study compared to the placebo group (n = 9) who had a mean increase of 0.3 events per hour. The 11.4 events per hour treatment benefit (between group difference in adjusted mean changes calculated using the ANOVA model) was significant at P = 0.014. Relevant data were not available to allow us to produce a meta‐analysis. </p> </section> <section id="CD009354-sec-0067"> <h5 class="title">6. Quality of life</h5> <p>The study investigators reported that for the 'Childhood Health Assessment Questionnaire' (CHAQ) and 'Health Assessment Questionnaire' (HAQ) at baseline the "Disability Index scores were 1.9 for the placebo group and 2.0 for the laronidase group (scale of 0 to 3, with 3 the most disabled) (<a href="./references#CD009354-bbs2-0001" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40. ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase 3 extension study of aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I). Journal of Inherited Metabolic Disease2006;29(Suppl 1):28. [ABSTRACT NO.: WS-9-4] [CENTRAL: 1000736] ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase III extension study of aldurazyme(laronidase) in mucopolysaccharidosis I. Clinical Therapeutics2007;29(Suppl C):S111. NCT00912925. Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I. clinicaltrials.gov/ct2/show/NCT00912925 (first posted 03 June 2009). WraithJE , ClarkeLA , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics2004;144(5):581-8. WraithJE , MuenzerJ , KolodnyEH , PastoresGM , BeckM , ClarkeLA . Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 96-week extension data. Journal of Inherited Metabolic Disease2005;28(Suppl 1):182. [ABSTRACT NO.: 360-P] [CENTRAL: 1000735] ">Wraith 2004</a>). Changes in the Disability Index after treatment were "small and did not differ between groups" (low‐quality evidence).  </p> </section> <section id="CD009354-sec-0068"> <h5 class="title">7. Mortality</h5> <p>There were no deaths in either group (low‐quality evidence) (<a href="./references#CD009354-bbs2-0001" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40. ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase 3 extension study of aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I). Journal of Inherited Metabolic Disease2006;29(Suppl 1):28. [ABSTRACT NO.: WS-9-4] [CENTRAL: 1000736] ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase III extension study of aldurazyme(laronidase) in mucopolysaccharidosis I. Clinical Therapeutics2007;29(Suppl C):S111. NCT00912925. Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I. clinicaltrials.gov/ct2/show/NCT00912925 (first posted 03 June 2009). WraithJE , ClarkeLA , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics2004;144(5):581-8. WraithJE , MuenzerJ , KolodnyEH , PastoresGM , BeckM , ClarkeLA . Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 96-week extension data. Journal of Inherited Metabolic Disease2005;28(Suppl 1):182. [ABSTRACT NO.: 360-P] [CENTRAL: 1000735] ">Wraith 2004</a>).  </p> </section> <section id="CD009354-sec-0069"> <h5 class="title">8. Effects on cognition</h5> <p>This outcome, based on standard age‐appropriate psychometric testing was not reported in the included study (<a href="./references#CD009354-bbs2-0001" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40. ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase 3 extension study of aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I). Journal of Inherited Metabolic Disease2006;29(Suppl 1):28. [ABSTRACT NO.: WS-9-4] [CENTRAL: 1000736] ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase III extension study of aldurazyme(laronidase) in mucopolysaccharidosis I. Clinical Therapeutics2007;29(Suppl C):S111. NCT00912925. Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I. clinicaltrials.gov/ct2/show/NCT00912925 (first posted 03 June 2009). WraithJE , ClarkeLA , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics2004;144(5):581-8. WraithJE , MuenzerJ , KolodnyEH , PastoresGM , BeckM , ClarkeLA . Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 96-week extension data. Journal of Inherited Metabolic Disease2005;28(Suppl 1):182. [ABSTRACT NO.: 360-P] [CENTRAL: 1000735] ">Wraith 2004</a>). </p> </section> <section id="CD009354-sec-0070"> <h5 class="title">9. Liver volume</h5> <p>Mean liver volume was used as a marker of storage material. In the laronidase group, 13 out of 18 (72%) participants with abnormal liver volumes at baseline attained normal volumes at week 26 versus 3 out of 14 (21%) in the placebo group. Overall, there was a significant difference in favour of the laronidase group, with mean liver volume decreasing by 18.9% in the laronidase group and increasing by 1.3% in the placebo group, MD 20.00 (95%CI 8.93 to 31.07) (<a href="./references#CD009354-fig-0006" title="">Analysis 1.6</a>).  </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009354-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009354-sec-0071"></div> <section id="CD009354-sec-0072"> <h3 class="title" id="CD009354-sec-0072">Summary of main results</h3> <p>The first use of enzyme replacement therapy (ERT) in mucopolysaccharidosis type I (MPS I) was described by Kakkis in 10 MPS I patients aged five to 22 years treated with recombinant human α‐L‐iduronidase for 52 weeks (<a href="./references#CD009354-bbs2-0006" title="KakkisED , MuenzerJ , TillerGE , WaberL , BelmontJ , PassageM , et al. Enzyme-replacement therapy in mucopolysaccharidosis I. New England Journal of Medicine2001;344(3):182-8. ">Kakkis 2001a</a>). This demonstrated clinical and biochemical improvement, and led to the 26‐week, randomised, placebo‐controlled study included in this review (<a href="./references#CD009354-bbs2-0001" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40. ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase 3 extension study of aldurazyme (laronidase) in mucopolysaccharidosis I (MPS I). Journal of Inherited Metabolic Disease2006;29(Suppl 1):28. [ABSTRACT NO.: WS-9-4] [CENTRAL: 1000736] ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ . A phase III extension study of aldurazyme(laronidase) in mucopolysaccharidosis I. Clinical Therapeutics2007;29(Suppl C):S111. NCT00912925. Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I. clinicaltrials.gov/ct2/show/NCT00912925 (first posted 03 June 2009). WraithJE , ClarkeLA , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics2004;144(5):581-8. WraithJE , MuenzerJ , KolodnyEH , PastoresGM , BeckM , ClarkeLA . Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 96-week extension data. Journal of Inherited Metabolic Disease2005;28(Suppl 1):182. [ABSTRACT NO.: 360-P] [CENTRAL: 1000735] ">Wraith 2004</a>). This study demonstrated statistically significant benefits in the primary outcomes of this review, i.e. level of urinary glycosaminoglycans (GAGs), respiratory function in the form of forced vital capacity (FVC) and endurance as measured by the six‐minute walk test (6MWT). In addition, there was improvement in mean liver volume and symptoms of sleep hypoventilation and apnoea. Laronidase was generally well‐tolerated with reported adverse effects being predominantly infusion related. No severe adverse events were reported. The majority of patients developed IgG antibodies, but these levels were declining in the majority of patients by the end of the study. </p> </section> <section id="CD009354-sec-0073"> <h3 class="title" id="CD009354-sec-0073">Overall completeness and applicability of evidence</h3> <p>The included study provided data on the short‐term efficacy and safety of laronidase in patients aged six to 43 years. The positive results seen in this study were reflected in the subsequent open‐label extension study (<a href="./references#CD009354-bbs2-0015" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40.">Clarke 2009</a>). The introduction of haemopoietic stem cell therapy has revolutionised the treatment of MPS I and should be the gold standard for treating Hurler syndrome. </p> </section> <section id="CD009354-sec-0074"> <h3 class="title" id="CD009354-sec-0074">Quality of the evidence</h3> <p>One study fulfilled the inclusion criteria and had a very small number of participants and was of low quality. In relation to the risk of bias, the main limitation was the lack of information with regards to allocation generation and concealment. </p> </section> <section id="CD009354-sec-0075"> <h3 class="title" id="CD009354-sec-0075">Potential biases in the review process</h3> <p>There are no obvious potential biases. All conflicting interests are declared.</p> </section> <section id="CD009354-sec-0076"> <h3 class="title" id="CD009354-sec-0076">Agreements and disagreements with other studies or reviews</h3> <p>The 45 participants included in the study were subsequently enrolled into a 3.5 year extension study (<a href="./references#CD009354-bbs2-0015" title="ClarkeLA , WraithJE , BeckM , KolodnyEH , PastoresGM , MuenzerJ , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics2009;123(1):229-40.">Clarke 2009</a>). This demonstrated long‐term clinical benefit with continued improvement in FVC, the 6MWT, sleep symptoms, shoulder flexion and '(Childhood Health Assessment Questionnaire' (CHAQ) and 'Health Assessment Questionnaire' (HAQ) scores. Laronidase continued to be well‐tolerated with infusion reactions being easily managed and the number of these decreasing after six months. One individual experienced an anaphylactic reaction and one patient died, but this was due to an unrelated treatment for an upper respiratory tract infection. Antibodies developed in 93% of participants, but 29% were seronegative at their last assessment. </p> <p>A large number of individuals are diagnosed at under five years of age and so would potentially benefit from ERT. As the first study did not include children aged under five years, a 52‐week, prospective, open‐label, multinational study of 20 children with MPS I under five years of age was conducted (<a href="./references#CD009354-bbs2-0010" title="Wraith JE,  BeckM ,  LaneR ,  van der PloegA ,  ShapiroE ,  XueY ,  et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics2007;120(1):e37-46. ">Wraith 2007</a>). This demonstrated its safety and efficacy in this age group at a dose of 0.58 mg/kg per week.  </p> <p>Giugliani conducted a 26‐week, randomised, open‐label, multinational study comparing three alternative regimens against the standard dose (<a href="./references#CD009354-bbs2-0004" title="GiuglianiR , RojasVM , MartinsAM , ValadaresER , ClarkeJTR , GoesJEC , et al. A dose-optimisation trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Molecular Genetics and Metabolism2009;96(1):13-9. ">Giugliani 2008</a>). The alternative dosing regimens were 1.2 mg/kg every two weeks, 1.2 mg/kg every week and 1.8 mg/kg every two weeks among 33 MPS I patients. The outcomes were no further reduction in urinary GAG excretion or liver volume when compared to standard dose. The safety profile at all doses was acceptable with infusion reactions occurring across all regimens, but the lowest number being in the approved dose group (35% versus 25% to 63%). There was one non‐treatment related death attributable to acute bronchitis. It was concluded that a dose of 0.58 mg/kg/week provided the best benefit‐to‐risk ratio with near‐maximal reductions in GAGs. The 1.2 mg/kg dose given every two weeks was deemed to be an acceptable alternative for those with difficulty receiving weekly infusions, but the long‐term effects are unknown.  </p> <p>While ERT is the mainstay of treatment in the majority of MPS disorders, haemopoietic stem cell transplantation (HSCT) is the gold standard treatment in severe MPS I patients diagnosed under 2.5 years of age. There is a juxtaposition of the two therapies with a recent European consensus review (<a href="./references#CD009354-bbs2-0003" title="deRueMH , BoelensJJ , DasAM , JonesSA , van derLeddJH , MahlaouiN , et al. Enzyme replacement therapy and / or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet Journal of Rare Disease2011;6(55):1-9. ">de Rue 2011</a>) reaching full consensus on several important issues: </p> <p> <ol id="CD009354-list-0012"> <li> <p>HSCT is the preferred treatment for those diagnosed before 2.5 years of age with Hurler syndrome; </p> </li> <li> <p>HSCT should be considered in those with an intermediate phenotype if there is a suitable donor though there is no data on efficacy in this group; </p> </li> <li> <p>MPS I patients who have not been transplanted or those whose grafts fail may benefit from ERT; </p> </li> <li> <p>ERT should be started at diagnosis and may be of value in patients awaiting HSCT to optimise pre‐transplant fitness. </p> </li> </ol> </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009354-fig-0001"> <p> <div class="table" id="CD009354-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Change in urinary GAG excretion</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Urinary GAG excretion in laronidase group (n = 21)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Urinary GAG excretion in placebo group (n = 22)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P‐value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Wraith 2004</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean reduction of 54.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean increase of 47.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Laronidase versus placebo, Outcome 1: Change in urinary GAG excretion</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/references#CD009354-fig-0001">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009354-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/urn:x-wiley:14651858:media:CD009354:CD009354-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Laronidase versus placebo, Outcome 2: Change from baseline in FVC (% of predicted normal)" data-id="CD009354-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/image_n/nCD009354-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/image_t/tCD009354-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Laronidase versus placebo, Outcome 2: Change from baseline in FVC (% of predicted normal) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/references#CD009354-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/image_n/nCD009354-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009354-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/urn:x-wiley:14651858:media:CD009354:CD009354-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Laronidase versus placebo, Outcome 3: Change from baseline in 6MWT" data-id="CD009354-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/image_n/nCD009354-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/image_t/tCD009354-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Laronidase versus placebo, Outcome 3: Change from baseline in 6MWT</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/references#CD009354-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/image_n/nCD009354-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009354-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/urn:x-wiley:14651858:media:CD009354:CD009354-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Laronidase versus placebo, Outcome 4: One or more infusion related reactions" data-id="CD009354-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/image_n/nCD009354-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/image_t/tCD009354-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Laronidase versus placebo, Outcome 4: One or more infusion related reactions</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/references#CD009354-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/image_n/nCD009354-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009354-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/urn:x-wiley:14651858:media:CD009354:CD009354-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Laronidase versus placebo, Outcome 5: Antibody production" data-id="CD009354-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/image_n/nCD009354-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/image_t/tCD009354-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Laronidase versus placebo, Outcome 5: Antibody production</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/references#CD009354-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/image_n/nCD009354-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009354-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/urn:x-wiley:14651858:media:CD009354:CD009354-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Laronidase versus placebo, Outcome 6: % change in liver volume" data-id="CD009354-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/image_n/nCD009354-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/image_t/tCD009354-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Laronidase versus placebo, Outcome 6: % change in liver volume</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/references#CD009354-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/media/CDSR/CD009354/image_n/nCD009354-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009354-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Laronidase compared with placebo for mucopolysaccharidosis type I</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults and children with mucopolysaccharidosis I </p> <p><b>Settings</b>: outpatient </p> <p><b>Intervention</b>: laronidase 0.58 mg / kg given weekly for 26 weeks </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Laronidase</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in urinary GAG excretion from baseline</p> <p>Follow‐up: 26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean increase of 47.3%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean reduction of 54.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N/A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt;0.001</p> <p>No standard deviations were given in the paper.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean percentage change from baseline in FVC (% predicted)</p> <p>Follow‐up: 26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean percentage change in FVC (% predicted) was ‐ 0.7 % (SD 5.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean percentage change was 5.6% higher (1.2 % higher to 9.96 % higher) in the laronidase group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in 6MWT (metres)</p> <p>Follow‐up: 26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in 6MWT was ‐18.4 metres (SD 67.5)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in 6MWT in the laronidase group was was 38.1 metres higher than the placebo group (1.7 metres lower to 77.9 metres higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our analysis shows a non significant difference between laronidase and placebo MD 38.10 (95% CI ‐1.68 to 77.88). </p> <p>The paper reports a significant difference favouring laronidase in a pre‐planned ANCOVA that took into account study centre, sex and baseline 6MWT, standing height and liver volume (P = 0.039). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infusion‐related reactions (number of participants with one or more reaction)</p> <p>Follow‐up: 26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>478 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>244 per 1000</b><br/>(72 to 817 per 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR</b> </p> <p><b>0.51</b> (0.15 to 1.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibody production: number of participants developing IgG antibodies</p> <p>Follow‐up: 26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Unable to calculate as assumed risk is zero</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR</b> </p> <p><b>385.4</b> (17.47 to 8500.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the laronidase group, 91% of patients (20 out of 22) developed IgG antibodies versus none in the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Changes in the Disability Index after treatment were "small and did not differ between groups" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No numerical results presented in the paper.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality: number of deaths</p> <p>Follow‐up: 26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There were no deaths in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>6MWT</b> : six‐minute walk test; <b>CI</b> : confidence interval; <b>FVC</b> : forced vital capacity; <b>GAG</b> : glycosaminoglycans; <b>OR</b>: odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded once due to an unclear risk of bias within the study from lack of information on process of randomisation and allocation concealment </p> <p>2. Downgraded once due to imprecision as the study had a small number of participants. There was no explanation of the sample size calculation and whether there were enough participants to show an effect. </p> <p>3. Downgraded twice due to imprecision as the study number was small and event rates were low. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/full#CD009354-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009354-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Laronidase versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Change in urinary GAG excretion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Change from baseline in FVC (% of predicted normal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 At week 26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Change from baseline in 6MWT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 At week 26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>38.10 [‐1.68, 77.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 One or more infusion related reactions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Antibody production <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 % change in liver volume <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 At week 26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Laronidase versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009354.pub5/references#CD009354-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009354.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009354-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009354-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009354-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD009354-note-0006">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009354\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009354\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009354\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009354\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009354\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009354\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009354\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009354\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009354\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009354\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009354\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009354\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009354\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009354\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009354\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009354\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009354\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009354\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009354.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009354.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009354.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009354.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009354.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726833862"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009354.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726833866"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009354.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9d529d84f480',t:'MTc0MDcyNjgzNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 